News

Promising phase 2 data for LY3041658 released during the Late-breaking Research session at the 2023 annual meeting.

In a shared session at AAD, Ramona Behshad, MD, FAAD, will present a hands-on surgical scar revision workshop using cadavers.

The latest phase 3 trial results were showcased in an AAD late-breaking research session.

Patients with squamous cell carcinoma who experience immunosuppression are at a greater risk.

Wu delves into her AAD involvement as she presents in sessions centered around the importance of patch testing and how clinical guidelines are created.

Expert warns lack of proper diagnosis and complete and thorough treatment of onychomycosis can lead to an endemic issue.

Designed to address the underlying causes of DEB, the investigational topical gene therapy shows great promise to improve quality of life for patients with this rare disorder.

Bhatia shares key pearls from his sessions at AAD 2023 discussing office politics and how to run a clinical research unit.

Victoria Barbosa, MD, FAAD, shares pearls on the clinical recognition and management of alopecia in Black women.

She and her colleagues illustrated the role of direct immunofluorescence plays in the evaluation of autoimmune blistering disorders.

Transgender and cisgender patients presenting with acne face differences in acne treatment and prescribing patterns.

According to his AAD 2023 session, Matarasso stresses it’s crucial to consider the type of patient you want as a loyal patient.

This AAD panel will feature a lively discussion on how to handle difficult or complex medical dermatology cases, with illustrative case studies on dermatomyositis, hidradenitis suppurativa, atopic dermatitis, and more.

The Skin of Color Society challenged dermatologists, residents, and medical students to address racial disparities in dermatologic care and shared best practices to serve patients of color.

Experts will gather for an “Acne Boot Camp” at the American Academy of Dermatology 2023 Annual Meeting to discuss best practices for treating patients with acne.

Han and colleagues will explore the most important factors to consider when selecting an appropriate biologic treatment in an upcoming panel at AAD.

The SUPERB applicator is cleared to address several aesthetic and cosmetic concerns, including lines, wrinkles, and more.

In part 2 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Among the more than 300 sessions to be held at this week's American Academy of Dermatology meeting in New Orleans, Louisiana, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Anna Bar, MD, FAAD returns to AAD as part of the interactive “How Would You Reconstruct It?” session.

This weekend's American Academy of Dermatology (AAD) meeting in New Orleans has key opinion leaders excited.

When combined with a low dosage of prednisone, methotrexate provided nearly complete or complete hair regrowth in up to 31.2% of patients with alopecia areata.

Dermavant’s ADORING 2 phase 3 trial met all primary and secondary endpoints.

Monica K. Li, MD, shares what to expect at her co-directed global microneedling techniques session at AAD 2023.

Treatment safety and efficacy for atopic dermatitis has seen significant growth over the last decade.

As sessions wrap up each day at AAD, there are numerous must-see places in New Orleans.

Researchers observed no difference in rate ratios between a 2009 to 2015 cohort and a 2016 to 2021 cohort.

Researchers reviewed nearly 7 years' worth of patch testing data to analyze trends in hand eczema in Latin America.

Danish researchers collected nearly 20 years of data to determine an association.

Adam Friedman, MD, FAAD, offers first-time AAD attendees tips on how to navigate the annual meeting in New Orleans.